TECOmedical Group

always your partner

Technical Information

Endostatin mouse/rat

Cat. No.:	BI-20742MR
Tests:	96
Method:	**ELISA**
Range:	0 – 32 nmol/l
LLOQ:	0.5 nmol/l (STD2 1 nmol/l)
Incubation time:	2 h / 30 min
Sample volume:	5 µl
Sample type:	Serum, plasma
Sample preparation:	Centrifuge freshly collected blood as soon as possible Store centrifuged samples at -20°C for longer storage. Samples are stable up to 3 freeze and thaw cycles. Hemolyzed or lipemic samples may cause erroneous results.
Reference values:	Mouse sera C57BL6JOlaHsd, 12 weeks (n=11): 6.7 ± 0.8 nmol/l Wildtype normal mice sera, 12 weeks, male (n=10): 5.4 ± 1.2 nmol/l Wildtype normal rat sera, 12 weeks, male (n=8): 2.5 ± 0.4 nmol/l
Species:	Mouse, rat

Intended use:

Endostatin, a 20-kDa C-terminal proteolytic fragment of collagen XVIII, is an endogenous angiogenesis inhibitor localized in the vascular basement membrane in various organs http://www.uniprot.org/uniprot/P39060). The biological functions of the endostatin-network involve SPARC, thrombospondin-1, glycosaminoglycans, collagens, and integrins. In animal studies, renal Endostatin expression preceded deteriorating kidney function and induced renal fibrosis in aging mice. In humans, Endostatin is expressed during the progression of renal fibrosis in tubular cells of injured tissue .In renal micro-vascular disease, observed in late stages of patients with chronic kidney disease, increased endostatin levels are possibly the consequence of enhanced extracellular matrix degradation.
Thus endostatin may become an important marker for progressive microvascular renal disease in patients with chronic kidney disease. Endostatin levels in blood are also likely to increase in patients with other microvascular tissue injuries, including atherosclerosis, myocardial- and brain ischemia. In ischemic stroke patients, high endostatin plasma levels predict a worse long-term clinical outcome. In a cohort of critically ill patients, plasma endostatin improved AKI prediction based on clinical risk factors. Endostatin has evolved as a molecular target and is currently under investigation in clinical trials.

Intended applications:

- Micro-vascular injury
- Chronic kidney disease
- Atherosclerosis
- Ischemia
- Sepsis
- Preeclampsia

For further information please contact / Für weitere Informationen wenden Sie sich bitte an / Pour plus d´informations, veuillez contacter:

www.tecomedical.com

Certified Quality-System mdc ISO 13485

A EUROBIO SCIENTIFIC COMPANY

Switzerland / Headquarters
TECO*medical* AG
Gewerbestrasse 10
4450 Sissach
Phone +41 61 985 81 00
Fax +41 61 985 81 09
Mail info@tecomedical.com

Germany
TECO*medical* GmbH
Wasserbreite 57
32257 Bünde
Phone +49 52 23 985 99 99
Fax +49 52 23 985 99 98
Mail info@tecomedical.com

Benelux
TECO*medical* Benelux BV
Prins Willem-Alexanderlaan 301
7311 SW Apeldoorn, The Netherlands
Phone +31 30 307 87 30
Fax +31 30 307 49 39
Mail benelux@tecomedical.com

Austria
TECO*medical* AG
Phone 0800 20 40 66
Fax 0800 20 40 55
Mail info@tecomedical.com